Pivotal REACH Study Aims to Transform Early Cancer Detection in West Virginia

In West Virginia, a pivotal clinical study known as the REACH study is underway, focusing on early cancer detection using advanced technology. The West Virginia University (WVU) Cancer Institute, alongside the WVU Departments of Family Medicine and Community Medicine and GRAIL, Inc., are at the forefront of this research. They are utilizing GRAIL's Galleri Multi-Cancer Early Detection (MCED) test, renowned for screening over 50 types of cancer.

This initiative seeks to integrate the MCED test into existing cancer screening protocols to enhance early detection, thereby reducing late-stage diagnoses. The study intends to evaluate the test's performance, especially among older adults, and its viability within the Medicare demographic.

The REACH study aims to recruit 50,000 participants from diverse clinical settings across North America, with 2,000 from WVU Medicine Primary Care locations in West Virginia. Participants will undergo the Galleri test up to three times annually, with results guiding healthcare providers and patients on necessary subsequent interventions.

Courtney Pilkerton, M.D., Ph.D., an associate professor and vice chair of research in the Department of Family and Community Medicine and the principal investigator of the study, highlights the study’s impact. "Trials like REACH, which explore multicancer early detection, could directly impact cancer identification and treatment in West Virginia, where the cancer burden is disproportionately high," she said.

West Virginia residents interested in participating are encouraged to consult with WVU Medicine primary care providers. Those needing to establish care can call 855-WVU-CARE for assistance.